+13.8%
ABNB vs MRNA
+27.9%
-14.1%
-37.2%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 3y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | -1.2% | +0.7% | -1.9% | -1.2% |
| 7D | -9.5% | -8.2% | -1.3% | -9.1% |
| 30D | -9.4% | +125.6% | -134.9% | -18.0% |
| 3M | +29.9% | +197.1% | -167.2% | +11.4% |
| 6M | +26.6% | +148.5% | -121.9% | +11.4% |
| YTD | +23.5% | +363.3% | -339.7% | -2.7% |
| 1Y | +35.8% | +462.0% | -426.1% | +2.4% |
| All | +13.8% | +27.9% | -14.1% | -9.5% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 3y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
3y analysis · Full analysis span regression · 6 months rolling